company background image
CBL

Control Bionics ASX:CBL Stock Report

Last Price

AU$0.14

Market Cap

AU$13.1m

7D

-3.3%

1Y

-67.8%

Updated

06 Dec, 2022

Data

Company Financials +
CBL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

CBL Stock Overview

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America.

Control Bionics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Control Bionics
Historical stock prices
Current Share PriceAU$0.14
52 Week HighAU$0.48
52 Week LowAU$0.12
Beta0
1 Month Change-23.68%
3 Month Change-27.50%
1 Year Change-67.78%
3 Year Changen/a
5 Year Changen/a
Change since IPO-87.71%

Recent News & Updates

Recent updates

Companies Like Control Bionics (ASX:CBL) Are In A Position To Invest In Growth

Jan 19
Companies Like Control Bionics (ASX:CBL) Are In A Position To Invest In Growth

We're Hopeful That Control Bionics (ASX:CBL) Will Use Its Cash Wisely

Sep 17
We're Hopeful That Control Bionics (ASX:CBL) Will Use Its Cash Wisely

Shareholder Returns

CBLAU Medical EquipmentAU Market
7D-3.3%0.02%1.0%
1Y-67.8%-7.5%-2.2%

Return vs Industry: CBL underperformed the Australian Medical Equipment industry which returned -7.5% over the past year.

Return vs Market: CBL underperformed the Australian Market which returned -2.2% over the past year.

Price Volatility

Is CBL's price volatile compared to industry and market?
CBL volatility
CBL Average Weekly Movement16.2%
Medical Equipment Industry Average Movement10.1%
Market Average Movement8.9%
10% most volatile stocks in AU Market15.9%
10% least volatile stocks in AU Market4.1%

Stable Share Price: CBL is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: CBL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2005n/aPeter Fordhttps://www.controlbionics.com

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America. The company offers NeuroNode Trilogy and NeuroNode3 systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a device to control a range of devices, including wheelchairs, dining robots, and gaming systems; Uno Touch, a speech generating device; and other sensors for multiple applications.

Control Bionics Limited Fundamentals Summary

How do Control Bionics's earnings and revenue compare to its market cap?
CBL fundamental statistics
Market CapAU$13.12m
Earnings (TTM)-AU$6.10m
Revenue (TTM)AU$4.81m

2.7x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CBL income statement (TTM)
RevenueAU$4.81m
Cost of RevenueAU$1.98m
Gross ProfitAU$2.84m
Other ExpensesAU$8.94m
Earnings-AU$6.10m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.067
Gross Margin58.92%
Net Profit Margin-126.72%
Debt/Equity Ratio0.4%

How did CBL perform over the long term?

See historical performance and comparison